Replies to post #50575 on Cytogenix (fka CYGX)

[downregul8]

Paulness – $30 buyout? I know it’s the weekend but I think you may be starting happy hour a little early. We’d be extremely lucky at a tenth of that – but even that won’t happen for a while. Big pharma’s typically don’t get involved until there has been some amount of human testing. Cygx is aware of this and has repeatedly indicated that they would seek help developing products in late stage trials. Since cygx knows the value of the product – enough to have net present value slides years ago – and since they know that they need to start the clinical testing before they can attract the much needed pharmaceutical partners, the question is - why is there no demonstrated sense of urgency on cygx’s part to move forward with the IND? If you believe that there is a market for these products (as I still do) then you’ve got to frustrated with the IND delays. Delays which to a great extent have been a choice.

[neo43]

"If Cytogenix could just" is truly the operative phrase with this company.

The science has so much potential, if Cytogenix could just produce a viable product that works, and if it can then just effectively market that product to make some money.

In other words, if Cytogenix could just act like a frigging business rather than a research institution producing nothing but patent applications, there might be some hope. But Malcolm has proven time after time after time -- year after year after year -- that he's got NO CLUE on how to do this.

While this isn't surprising considering Malcolm's almost exclusively academic background, he's also proven amazingly incapable of learning about how to run a business. He's had 6 years(?) of on-the-job training and still seems totally clueless -- he doesn't even seem to have the ability to learn from his screw-ups. How anyone can still have faith in him is beyond my comprehension.